GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Novonesis (Novozymes) B (OTCPK:NVZMY) » Definitions » Ending Cash Position

NVZMY (Novonesis (Novozymes) B) Ending Cash Position : $293 Mil (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Novonesis (Novozymes) B Ending Cash Position?

Novonesis (Novozymes) B's Ending Cash Position for the quarter that ended in Dec. 2024 was $293 Mil.

Novonesis (Novozymes) B's quarterly Ending Cash Position declined from Dec. 2023 ($163 Mil) to Jun. 2024 ($0 Mil) but then increased from Jun. 2024 ($0 Mil) to Dec. 2024 ($293 Mil).

Novonesis (Novozymes) B's annual Ending Cash Position increased from Dec. 2022 ($148 Mil) to Dec. 2023 ($163 Mil) and increased from Dec. 2023 ($163 Mil) to Dec. 2024 ($293 Mil).


Novonesis (Novozymes) B Ending Cash Position Historical Data

The historical data trend for Novonesis (Novozymes) B's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novonesis (Novozymes) B Ending Cash Position Chart

Novonesis (Novozymes) B Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 193.07 146.31 148.00 163.25 293.19

Novonesis (Novozymes) B Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Jun24 Dec24
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 152.47 167.79 163.25 - 293.19

Novonesis (Novozymes) B Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Novonesis (Novozymes) B's Ending Cash Position for the fiscal year that ended in Dec. 2024 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=156.754+136.44
=293

Novonesis (Novozymes) B's Ending Cash Position for the quarter that ended in Dec. 2024 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=273.089+20.105
=293


Novonesis (Novozymes) B Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Novonesis (Novozymes) B's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.


Novonesis (Novozymes) B Business Description

Address
Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs around 10,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.

Novonesis (Novozymes) B Headlines

From GuruFocus

Q1 2022 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q2 2020 Novozymes A/S Trading Update Call Transcript

By GuruFocus Research 02-14-2024

Novozymes A/S Annual Shareholders Meeting Transcript

By GuruFocus Research 02-14-2024

Q2 2020 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Novozymes A/S Annual Shareholders Meeting Transcript

By GuruFocus Research 02-14-2024

Novonesis AS's Dividend Analysis

By GuruFocus Research 04-30-2024

Q1 2023 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024

Q4 2020 Novozymes A/S Earnings Call Transcript

By GuruFocus Research 02-14-2024